Migden MR, Berkin C, Chang AL, al. E. Interim Analysis of Phase 2 Results for Cemiplimab, a Human Monoclonal Antibody to Programmed Death-1, in Patients with Locally Advanced Cutaneous Squamous Cell Carcinoma. J of Skin [Internet]. 2018 Dec. 17 [cited 2024 Jul. 4];2:S77. Available from: https://jofskin.org/33014/index.php/skin/article/view/473